Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acitretin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 12/20 | 0.45 |
| ▸ | RARG known ✓ | P13631 | 9/20 | 0.45 |
| ▸ | RARA known ✓ | P10276 | 6/20 | 0.45 |
| ▸ | RARB known ✓ | P10826 | 6/20 | 0.45 |
| ▸ | RXRB known ✓ | P28702 | 4/20 | 0.45 |
| ▸ | RXRG known ✓ | P48443 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.72 |
| ▸ | PGR | P06401 | 2/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acitretin SCHEMBL159360 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL29883491 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL5028866 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL29496318 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL2280089 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL5053805 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL10750446 | 0.99 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL4443721 | 0.99 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL9856594 | 0.94 | ALDH1A1 (0.89) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| SCHEMBL10750080 | 0.94 | ALDH1A1 (0.89) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14418 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026104588-A1 | UROLITHIN COMBINATION | AMAZENTIS SA (CH) | 2026-05-21 | — | — | WO | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260115115-A1 | TYROTHRICIN FOR USE IN THE TREATMENT OR PROPHYLAXIS OF BODY ODOUR AND PREPARATIONS THEREFOR | LEIBBRAND THOMAS (DE) | 2026-04-30 | — | — | US | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-12582593-B2 | Oral care compositions for gum health | THE PROCTER & GAMBLE COMPANY (US) | 2026-03-24 | — | — | US | claimed |
| US-20260070959-A1 | T-Cell Modulatory Chimeric Molecules and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260053855-A1 | Modified Cytotoxic T Cells and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-02-26 | — | — | US | claimed |
| US-4900478-A | SKIN DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-02-13 | — | — | US | claimed |
| US-4889847-A | USED IN CONJUCTION WITH A RETINOID COMPOUND | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-12-26 | — | — | US | claimed |
| US-4888342-A | APPLYING RETINOID | KLIGMAN ALBERT M (US) | 1989-12-19 | — | — | US | claimed |
| US-4877805-A | REVERSING COLLAGEN FIBER LOSS BY APPLYING TO FACE | KLIGMAN ALBERT M (US) | 1989-10-31 | — | — | US | claimed |
| WO-1988005653-A1 | TOPICAL COMPOSITION FOR STIMULATING HAIR GROWTH WITH STABLE FREE RADICALS | PROCTOR PETER H (US) | 1988-08-11 | — | — | WO | claimed |
| EP-0263492-A1 | Retinoids, their preparation and use as pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1988-04-13 | — | — | EP | claimed |
| WO-1988000466-A1 | METHODS FOR TREATMENT OF SUNDAMAGED HUMAN SKIN WITH RETINOIDS | KLIGMAN ALBERT M (US) | 1988-01-28 | — | — | WO | claimed |
| EP-0002533-B1 | USE OF RETINOIDS AS MEDICINES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-06-25 | — | — | EP | claimed |
| US-4215215-A | 9-Phenyl-nonate traene compounds | HOFFMANN-LA ROCHE INC. (US) | 1980-07-29 | — | — | US | claimed |
| US-4105681-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-08-08 | — | — | US | claimed |